⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27709216 | 0.88 | PTPN1 (0.42) | — | |
| SCHEMBL11102141 | 0.81 | — | — | |
| SCHEMBL29950540 | 0.79 | ALDH1A1 (0.43) | — | |
| SCHEMBL7603557 | 0.78 | MEN1 (0.33) | — | |
| SCHEMBL2822798 | 0.76 | CYP4F2 (0.41) | — | |
| SCHEMBL2825318 | 0.76 | CYP1A2 (0.45) | — | |
| SCHEMBL9535519 | 0.74 | SMN1; SMN2 (0.35) | — | |
| SCHEMBL752460 | 0.74 | SMN1; SMN2 (0.43) | — | |
| SCHEMBL17984802 | 0.72 | — | — | |
| SCHEMBL5263447 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188075-A1 | SUBSTITUTED HETEROCYCLIC CSNK1 INHIBITORS | THE BROAD INSTITUTE, INC. | 2025-06-12 | — | — | US | disclosed |
| CN-113330000-B | 3-Carbonylamino-5-cyclopentyl-1 FI-pyrrole compounds having inhibitory activity on CDK2 | 辉瑞公司 | 2024-12-24 | — | — | CN | disclosed |
| EP-4469457-A1 | SUBSTITUTED HETEROCYCLIC CSNK1 INHIBITORS | The Broad Institute Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| US-20240294506-A1 | CDK2 INHIBITORS | PFIZER INC. (US) | 2024-09-05 | — | — | US | disclosed |
| US-11773082-B2 | CDK2 inhibitors | PFIZER INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773082-B2 | CDK2 inhibitors | PFIZER INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11718603-B2 | CDK2 inhibitors | PFIZER INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718603-B2 | CDK2 inhibitors | PFIZER INC. (US) | 2023-08-08 | — | — | US | disclosed |
| WO-2023147015-A1 | SUBSTITUTED HETEROCYCLIC CSNK1 INHIBITORS | THE BROAD INSTITUTE, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| EP-3917913-A2 | 3-CARBONYLAMINO-5-CYCLOPENTYL-1H-PYRAZOLE COMPOUNDS HAVING INHIBITORY ACTIVITY ON CDK2 | Pfizer Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| WO-2007138485-A2 | PPAR MODULATORS | EVOLVA SA (US) | 2007-12-06 | — | — | WO | disclosed |
| US-5693657-A | USEFUL FOR TREATING HYPERCHOLESTEROLEMIA OR ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 1997-12-02 | — | — | US | disclosed |
| US-5646170-A | ACYLCOENZYME A:CHOLESTEROL ACYLTRANSFERASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1997-07-08 | — | — | US | disclosed |
| EP-0684945-A1 | HETEROCYCLIC-SUBSTITUTED ALKYL AMIDE ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1995-12-06 | — | — | EP | disclosed |
| US-5441975-A | Anticholesterol agent | WARNER-LAMBERT COMPANY (US) | 1995-08-15 | — | — | US | disclosed |
| US-5366987-A | Enzyme inhibitors, anticholesterol | WARNER-LAMBERT COMPANY (US) | 1994-11-22 | — | — | US | disclosed |
| WO-1994019330-A1 | HETEROCYCLIC-SUBSTITUTED ALKYL AMIDE ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1994-09-01 | — | — | WO | disclosed |
| EP-0026928-B1 | 3,4-DIARYLISOXAZOL-5-ACETIC ACID COMPOUNDS, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICALS CONTAINING THE SAME | CDC Life Sciences Inc. (CA) | 1984-01-25 | — | — | EP | disclosed |
| US-4327222-A | REACTING AN ARYL SUBSTITUTED KETONE WITH HYDROXYLAMINE TO FORM OXIME, THEN CYCLIZATION WITH BUTYLLITHIUM | CDC LIFE SCIENCES INC. (CA) | 1982-04-27 | — | — | US | disclosed |
| EP-0026928-A1 | 3,4-Diarylisoxazol-5-acetic acid compounds, process for preparing the same, and pharmaceuticals containing the same | CDC Life Sciences Inc. (CA) | 1981-04-15 | — | — | EP | disclosed |